Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia
暂无分享,去创建一个
Jing Ma | Xiaotu Ma | Jinghui Zhang | Michael Edmonson | Michael Rusch | Julie M Gastier-Foster | John Easton | Panduka Nagahawatte | Daniela S Gerhard | David A Wheeler | Gang Wu | Donna M Muzny | Michael C. Rusch | Michael N. Edmonson | M. Loh | J. Downing | M. Relling | D. Muzny | D. Wheeler | D. Gerhard | M. Edmonson | J. Gastier-Foster | H. Doddapaneni | O. Hampton | Jing Ma | C. Mullighan | Guangchun Song | J. Easton | Gang Wu | Xiaotu Ma | S. Hunger | C. Willman | M. Rusch | Panduka Nagahawatte | D. Yergeau | Jinghui Zhang | Bhavin Vadodaria | M. Devidas | Malcolm A. Smith | J. G. Auvil | W. Carroll | R. Harvey | I. Chen | Jaime M. Guidry Auvil | Donald Yergeau | Bhavin Vadodaria | Guangchun Song | Oliver A Hampton | Mary V Relling | James R Downing | Stephen P Hunger | William L Carroll | Meenakshi Devidas | Charles G Mullighan | Malcolm A Smith | Mignon L Loh | HarshaVardhan Doddapaneni | Cheryl L Willman | I-Ming Chen | Richard C Harvey | Jaime M Guidry Auvil | D. Muzny | M. Loh
[1] G. Barton,et al. Randomised controlled trial , 2016 .
[2] M. Relling,et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? , 2012, Blood.
[3] M. Loh,et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[4] S. Armstrong,et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in pediatric acute lymphoblastic leukemia , 2014, Nature Communications.
[5] A. Ferrando,et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL , 2013, Nature Medicine.
[6] J. Potter,et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. , 2008, Gastroenterology.
[7] W. Evans,et al. Relapse specific mutations in NT5C2 in childhood acute lymphoblastic leukemia , 2013, Nature Genetics.
[8] Jacob D. Jaffe,et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia , 2013, Nature Genetics.
[9] Kenneth H. Buetow,et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.
[10] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[11] M. Loh,et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study , 2008, Leukemia.
[12] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[13] J. Geddes,et al. What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.
[14] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[15] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[16] D. Campana,et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. , 2012, Blood.
[17] Ken Chen,et al. Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.
[18] Dario Campana,et al. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. , 2009, Hematology/oncology clinics of North America.
[19] James R. Downing,et al. Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.
[20] M. Greaves,et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. , 2010, Blood.
[21] K. Anderson,et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. , 2009, Blood.
[22] R. Wade,et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. , 2013, The Lancet. Oncology.
[23] Michael N. Edmonson,et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.
[24] J. Harbott,et al. Key Treatment Questions in Childhood Acute Lymphoblastic Leukemia: Results in 5 Consecutive Trials Performed by the ALL-BFM Study Group From 1981 to 2000 , 2013, Klinische Pädiatrie.
[25] S. Sallan,et al. Therapeutic approaches to haematological malignancies in adolescents and young adults , 2014, British journal of haematology.
[26] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[27] M. Greaves,et al. Origins of chromosome translocations in childhood leukaemia , 2003, Nature Reviews Cancer.